Market Place
Sourcing Support
Top drugs and pharmaceutical companies of 2019 by revenues
Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-
Analyzing over US$ 90 billion of Medicare Prescription Drug (Part D) Spending in 2016
This week, PharmaCompass
reviews the recently released data on prescription drugs paid for under th
Top drugs by sales in 2017: Who sold the blockbuster drugs?
The year 2017 was a landmark year for pharmaceutical
industries in the US and Europe, with a sharp i
Teva to sell assets to reduce debt, lay-off 7,000 workers; Shkreli awaits sentence
This week in Phispers, we look at the growing troubles at Teva. The company plans to divest non-core
Chemical entities SHINE in the top 10 fastest-growing drugs of 2016
Global
pharmaceutical companies are increasingly focusing on the development of new
biologics. In fa
Top drugs by sales in 2016: Who sold the blockbuster drugs?
The year 2016 finished with a whimper insofar as mergers and acquisitions (M&As) were concerned.
FDA’s 2016 Approvals of New Drugs, Formulations, Strengths & More
After 2 years of sky-high approval numbers, the US Food and Drug Administration’s (FDA) Center
Trump’s comments on drug prices sink pharma stocks; Teva lowers guidance by $ 1 billion
The New
Year began with the JP Morgan Healthcare Conference— the drug industry’s annual
Drug costs and prescription trends in the United States: Analyzing Medicare’s $121 billion spend
In less than three weeks, Donald Trump will assume office as the
President of the United States. He
India steps up efforts to improve drug quality; Allergan vows to limit price hikes
This week, Phispers has two news items that demonstrate Indian government’s keenness to improv
